Improved Management of the Advanced Nonseminomatous Testis Cancer
DOI:
https://doi.org/10.32635/2176-9745.RBC.1984v30n2.3379Keywords:
Testicular Neoplasms, Combined Modality TherapyAbstract
With the VAB-6 program about 90% (54/59) of patients with stage III and bulky stage II disease achieved complete remission and eighty percent remain free of disease. Patients with minimal metastatic disease can usually be treated successfully with chemotherapy alone, while patients with advanced disease frequently required combined treatment with chemotherapy and surgery in order to achieve complete remission. Most patients without a teratomatous component in the testis tumor will achieve complete remission with chemotherapy alone, whereas patients with a teratomatous componente are more likely to require the combined approach of chemotherapy and surgery to achieve disease free status. Pure seminoma was apparently the most responsive and pure choriocarcinoma the least responsive histologic type of testis tumor to the combination chemotherapy. The incidence of a residual mature teratoma in the resected specimem has increased with the improved efficacy of chemotherapy. High complete remission rates and a short duration of treatment ensure rapid return of afflicted individuals to productive life, thus, fulfilling a most importante goal of treatment.
Downloads
References
Cancer Patient Survival. Report No. NIH: 77-992, U.S. Department of Health, Education, and Welfare, Washington, D.C., 1976.
BATATA, M.A.; UNAL, A. – The role of radiation therapy in relation to stage and histology of testicular cancer. Semin. Oncol., 1979. DOI: https://doi.org/10.1016/0360-3016(79)91018-6
BREDAEL, JJ.; VUGRIN, D.; WHITMORE, W.F., Jr. – Selected Experience With Surgery and Chemotherapy in the Treatment of Nonseminomatous Testis Tumors. J. Urol., (in press).
WHITMORE, W.F., Jr. – Surgical treatment of adult germinal testis tumors. Semin. One., 6:55-68, 1979.
LI, M.C.; WHITMORE, W.F.; GOLBEY, R.B., et al. — Effects of combined drug therapy on metastatic cancer of testis. J. Amer. Med. Assoc., 174:1291-1299, 1960. DOI: https://doi.org/10.1001/jama.1960.03030100059013
WITTES, R.E.; YAGODA, A.; SILVAY, O., et al. — Chemotherapy of germ cell tumors of the testis. 1. induction of remission with vinblastine, actinomycin D, and bleomycin. Cancer., 37: 637-645, 1976. DOI: https://doi.org/10.1002/1097-0142(197602)37:2<637::AID-CNCR2820370205>3.0.CO;2-M
CHENG, E.; CVITKOVIC, E.; WITTES, R.E., et al — Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer., 42: 2162-2168, 1978. DOI: https://doi.org/10.1002/1097-0142(197811)42:5<2162::AID-CNCR2820420512>3.0.CO;2-I
REYNOLDS, T.F.; VUGRIN, D.; CVITKOVIC, E.; CHENG, E.; BRAUN, D.W.; 0'HEIR, M.A.; DUKEMAN, M.E.; WHITMORE, W.F., Jr.; GOLBEY, R.B. - VAB-3 Combination Chemotherapy of Metastatic Testicular Cancer. Cancer., 48: 888-898, 1981. DOI: https://doi.org/10.1002/1097-0142(19810815)48:4<888::AID-CNCR2820480405>3.0.CO;2-D
VUGRIN, D.; CVITKOVIC, E.; WHITMORE, W.F., Jr.; CHENG, E.; GOLBEY, R.B. - VAB-4 Combination Chemotherapy in the Treatment of Metastatic Testis Tumors. Cancer., 47: 833-839, 1981. DOI: https://doi.org/10.1002/1097-0142(19810301)47:5<833::AID-CNCR2820470502>3.0.CO;2-H
VUGRIN, D.; WHITMORE, W.F., Jr.; GOLBEY, R.B. - VAB-5 Combination Chemotherapy in Prognostically Poor Risk Patients With Germ Cell Tumors. Cancer., (in press).
VUGRIN, D.; HERR, H.W.; WHITMORE, W.F., Jr.; SOGANI, P.C.; GOLBEY, R.B. - VAB-6 Combination Chemotherapy in Disseminated Cancer of the Testis. Annals. Int. Med., 95 59-61, 1981, DOI: https://doi.org/10.7326/0003-4819-95-1-59
VUGRIN, D.; HERR, H.; SOGANI, P.; WHITMORE, W.; GOLBEY, R. — VAB-6 Without Maintenance: Progress in Chemotherapy of Testicular Germ Cell Tumors (GCT). Proc. Amer. Soc. Clin, Oneol., 22: 474, 1981.
VUGRIN, D.; WHITMORE, W.F., Jr.; GOLBEY, R.B. - VAB-6 Combination Chemotherapy Without Maintenance in Treatment of Disseminated Caneer of the Testis. Cancer., (in press).
VUGRIN, D.; WHITMORE, W.F., Jr.; SOGANI, P.C.; BAINS, M.; HERR, H.W.; GOLBEY, R.B. - Combined Chemotherapy and Surgery in Treatment of Advanced Germ Cell Tumors. Cancer., 47:2228-2231, 1981. DOI: https://doi.org/10.1002/1097-0142(19810501)47:9<2228::AID-CNCR2820470920>3.0.CO;2-D
VUGRIN, D.; WHITMORE, W.F.; GOLBEY, R.B. - Effect of Shorter Induction Intervals on Complete Remisson (CR) Rates In Advanced Nonseminomatous Germ Cell Tumors of Testis (NSGCTT). Proc. Amer. Assoc. Cancer. Res., 23:148, 1982.
VUGRIN, D.; WHITMORE, W.F., Jr.; HERR, H.; SOGANI, P.; GOLBEY, R.B. - Indication for Retroperitoneal Lymph Node Dissection (RPLND) After Chemotherapy for Advanced Nonseminomatous Germ Cell Testis Cancer (NSGCT). Proc. Amer. Soc. Clin. Oncol., 1: 113, 1982.
VUGRIN, D.; WHITMORE, W.; OCHOA, M.; GOLBEY, R. – Cis diamminedichio rop latinum (II) (CDDP) in combination chemotherapy of metastatic seminoma. Proc. Amer. Assoe. Cenc. Res. (Canc. Res.), 22:166, 1981.
WHITMORE, W.F., Jr.; VUGRIN, D.; GOLBEY, R. - Prognostic Significance of Choriocarcinoma Elements in Testis Cancer. Proc. Amer. Soc. Clin. Oncol., 1:115, 1982.
VUGRIN, D.; CVITKOVIC, E.; POSNER, J.; HAJDU, S.; GOLBEY, R.B. - Neurological Complications of Malignant Germ Cell Tumors of the Testis: Biology of Brain Metastases. Cancer., 44: 2349-2353, 1979. DOI: https://doi.org/10.1002/1097-0142(197912)44:6<2349::AID-CNCR2820440652>3.0.CO;2-8
VUGRIN, D.; WHITMORE, W.F., Jr.; BAINS, M.; GOLBEY, R.B. - Role of Chemotherapy and Surgery in the Treatment of Thoracic Metastases from Nonseminomatous Germ Cell Testis Tumors. Câncer., (in press).
FRIEDMAN, A.; VUGRIN, D.; NISSELBAUM, J.; GOLBEY, R. - Prognostic Significance of Serum Tumor Biomarkers (TM), Alpha Feto Protein (AFP), Beta Subunit of Human Chorionic Gonadotrophin (bHCG), and Lactate Dehydrogenase (LDH) in Nonseminomatous Germ Cell Tumors (NSGCT). Proc Amer. Soc. Clin. Oncol., 21: 323, 1980.
